Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb808 + Pembrolizumab in Advanced Solid Tumors
NCT05585034Phase 1Completed
- Sponsor
- Xencor
- Start
- Dec 2022
- Primary completion
- May 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of xmab808 in prostate cancer (PCa), Epithelial Ovarian Cancer (EOC), head and neck squamous cell carcinoma (HNSCC) and 6 more, sponsored by Xencor. Primary endpoints: Incidence of treatment-emergent adverse events up to 5 years and Incidence of dose-limiting toxicities at 49 days. Started Dec 2022; status: completed.
02
Drugs
xmab808
03
Conditions
prostate cancer (PCa)Epithelial Ovarian Cancer (EOC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05585034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05585034.